Drug
Nebulized Ensifentrine
Nebulized Ensifentrine: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nebulized Ensifentrine Suspension; 3 mg NCT06559150 | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
Latest
No recent events.
Follow Nebulized Ensifentrine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.